Quick answer: latest quarter results, by ticker or company name

Reported Q: Q2 2024 Rev YoY: 0.0% EPS YoY: -3.7% Move: -8.73%

Regen BioPharma Inc

RGBPP

$0.0251 -8.73%

Exchange OTC Sector Healthcare Industry Biotechnology

Q2 2024

Published: Apr 24, 2024

Company Status Snapshot

Fast view of the latest quarter outcome for RGBPP

Reported

Report Date

Apr 24, 2024

Quarter Q2 2024

Revenue

59.07K

YoY: 0.0%

EPS

-0.03

YoY: -3.7%

Market Move

-8.73%

Previous quarter: Q1 2024

Follow this company to get upcoming quarter alerts automatically.

Earnings Highlights

Revenue of $0.06M up 0% year-over-year
EPS of $-0.03 decreased by 3.7% from previous year
Gross margin of 70.9%
Net income of -122.47K
"N/A" - N/A

RGBPP

Company RGBPP

Period Q2 2024

Currency USD

Report Type Quarterly Earnings

Generated Feb 9, 2026

Executive Summary

Regen BioPharma reported QQ2 2024 results with flat quarterly revenue and a material net loss driven by aggressive operating expenses and substantial depreciation, despite a healthy gross margin. Revenue for the quarter was 59,065 USD, with gross profit of 41,850 USD and a gross margin of approximately 70.85%. However, operating expenses totaled 160,135 USD, led by General and Administrative spend of 120,002 USD and Research and Development spend of 40,133 USD, resulting in operating income of -101,071 USD and an EBITDA of -101,070 USD. Net income declined to -122,473 USD, implying ongoing cash-burn dynamics.

Key Performance Indicators

Revenue

Stable

59.07K

QoQ: 0.00% | YoY: 0.00%

Gross Profit

Decreasing

41.85K

70.85% margin

QoQ: -5.03% | YoY: -29.15%

Operating Income

Decreasing

-101.07K

QoQ: 17.83% | YoY: -28.19%

Net Income

Decreasing

-122.47K

QoQ: 65.01% | YoY: -122.77%

EPS

Decreasing

-0.03

QoQ: 68.04% | YoY: -3.67%

Revenue Trend

Margin Analysis

Financial Highlights

Revenue: 59,065 (YoY 0.00%, QoQ 0.00%)
Gross Profit: 41,850 (YoY -29.15%, QoQ -5.03%)
Operating Income: -101,071 (YoY -28.19%, QoQ +17.83%)
Net Income: -122,473 (YoY -122.77%, QoQ +65.01%)
EPS: -0.0311 (YoY -3.67%, QoQ +68.04%)
EBITDA: -101,070 (EBITDA Margin: -1.71%)
Weighted Avg Shares: 3,941,013 (diluted: 3,941,013)
Cash flow from operations: -209,321 USD
Net change in cash: -46,383 USD
Cash at end of period: 78,115 USD
Free cash flow: -209,321 USD
Current ratio: 0.024
Quick ratio: 0.023
Cash ratio: 0.015

Income Statement

Metric	Value	YoY Change	QoQ Change
Revenue	59.07K	0.00%	0.00%
Gross Profit	41.85K	-29.15%	-5.03%
Operating Income	-101.07K	-28.19%	17.83%
Net Income	-122.47K	-122.77%	65.01%
EPS	-0.03	-3.67%	68.04%

Key Financial Ratios

Gross Profit Margin

Excellent

70.90%

Gross profit margin is exceptional, indicating strong pricing power and operational efficiency

Operating Profit Margin

Weak

-1.71%

Operating margin is below industry norms, profitability concerns

Net Profit Margin

Weak

-2.07%

Net profit margin is below industry norms, profitability concerns

Return on Assets

Weak

-0.87%

Return on assets suggests inefficient capital allocation

Return on Equity

Weak

2.37%

Return on equity suggests inefficient capital allocation

Current Ratio

Concern

0.02

Current ratio below safe levels, potential liquidity risk

Debt to Equity

Conservative

-0.13

Debt-to-equity shows conservative leverage and low financial risk

P/E Ratio

Negative

-5.42x

Negative earnings make P/E ratio not meaningful

Price to Book

Undervalued

-0.51x

Trading below book value, potential value opportunity or distressed

Historical Earnings Comparison

Period	Revenue ($M)	EPS ($)	YoY Growth	Report
Q1 2025	0.06	-0.03	-0.5%	View
Q4 2024	0.06	-0.03	+0.5%	View
Q3 2024	0.06	-0.03	+0.6%	View
Q2 2024	0.06	-0.03	+0.0%	View
Q1 2024	0.06	-0.10	+0.0%	View

RGBPP

Regen BioPharma Inc

Q4 2024 Report

Regen BioPharma Inc (RGBPP) QQ4 2024 Financial Analysis — Nascent biotech facing liquidity constraints with modest topline progression and meaningfu...

Read full report

RGBPP

Regen BioPharma Inc

Q1 2025 Report

Regen BioPharma Inc (RGBPP) QQ1 2025 Results – Elevated Losses, Tight Liquidity and Early-Stage Biotech Risk in Regenerative Immuno-Oncology...

Read full report

RGBPP

Regen BioPharma Inc

Q3 2024 Report

Regen BioPharma Inc (RGBPP) QQ3 2024 Results: Revenue Flat, Substantial Cash Burn, and Liquidity Strain in a Nanotech Biotech Research Portfolio...

Read full report

RGBPP

Regen BioPharma Inc

Q1 2024 Report

Regen BioPharma Inc (RGBPP) QQ1 2024 Earnings Analysis: Modest Revenue with High R&D/G&A Burn, Liquidity Imperatives in an Early-Stage Regenerative Bi...

Read full report

Regen BioPharma Inc (RGBPP) Q2 2024 Earnings Report

Company Status Snapshot

Earnings Highlights

Executive Summary

Key Performance Indicators

Revenue Trend

Margin Analysis

Financial Highlights

Income Statement

Key Financial Ratios

Management Insights Available for Members

Peer Comparison Available for Members

Investment Outlook & SWOT Available for Members

Historical Earnings Comparison

More RGBPP Quarterly Reports

RGBPP

RGBPP

RGBPP

RGBPP

Q2 2024 Reports in Healthcare Sector

RGBP

Related Financial Data

Sector Analysis: Healthcare

RGBPP Full Profile

RGBPP Financial Statements

Earnings Calendar